Zachary Roberts, EVP of R&D at Allogene Therapeutics ($ALLO), made two open market sales totaling about $104 thousand over the last year. His most recent sale occurred on February 2, 2026. These sales rank 9,513th among 11,678 insiders in our database, where the average is $8.6 million across about 6.4 transactions. Roberts made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | A | Restricted Stock Unit | 203307 | $0.00 | 203,307.0000 | 224,730,144 | 9999.99% | 0.09% |
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | A | Stock Option (Right to buy) | 718763 | $0.00 | 718,763.0000 | 224,730,144 | 9999.99% | 0.32% |
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | S | Common Stock | 35700 | $1.77 | 581,166.0000 | 224,730,144 | 5.79% | 0.02% |
| Jan. 21, 2026 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | S | Common Stock | 26269 | $1.56 | 616,866.0000 | 224,730,144 | 4.08% | 0.01% |
| Feb. 3, 2025 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | S | Common Stock | 18832 | $1.70 | 643,135.0000 | 0 | 2.84% | 0.00% |
| Jan. 24, 2025 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | A | Common Stock | 173913 | $0.00 | 661,967.0000 | 0 | 35.63% | 0.00% |
| Jan. 24, 2025 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | A | Stock Option (Right to buy) | 614844 | $0.00 | 614,844.0000 | 0 | 9999.99% | 0.00% |
| Jan. 21, 2025 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | S | Common Stock | 27199 | $1.78 | 488,054.0000 | 0 | 5.28% | 0.00% |
| Jan. 25, 2024 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | A | Stock Option (Right to buy) | 494949 | $0.00 | 494,949.0000 | 0 | 9999.99% | 0.00% |
| Jan. 25, 2024 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | A | Common Stock | 140000 | $0.00 | 515,253.0000 | 0 | 37.31% | 0.00% |
| Jan. 22, 2024 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | F | Common Stock | 24690 | $3.17 | 375,253.0000 | 0 | 6.17% | 0.00% |
| March 22, 2023 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | A | Common Stock | 148035 | $0.00 | 399,943.0000 | 0 | 58.77% | 0.00% |
| Jan. 20, 2023 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | A | Common Stock | 251908 | $0.00 | 251,908.0000 | 0 | 9999.99% | 0.00% |
| Jan. 20, 2023 | Allogene Therapeutics, Inc. | $ALLO | Roberts Zachary | EVP of R&D | A | Stock Option (Right to Buy) | 873015 | $0.00 | 873,015.0000 | 0 | 9999.99% | 0.00% |